Alexza (ALXA) is facing the FDA Advisory Panel on December 12th 2011. The Panel is gonna vote on the approvability of the company's AZ-004 Adasuve™ (Staccato® Loxapine) drug technology.
I think majority of the Panel will vote "yes" for the approval of Alexza's drug technology. This is because, although there are safer alternative ways of administering this drug, Alexza's techonlogy works faster and better. Also, this is the first technology of its kind. Why not approve it and give it chance for improvement in the future? So, I predict something like an 11-2 positive vote, that is more that 80% of the panel supporting the approval of Adasuve™ (Staccato® Loxapine). Alexza has also submitted application for approval in Europe.